Skip to content

In the BioHarmony Drug Report Database

Botulinum toxin type a

Dysport, Nuceiva (botulinum toxin type a) is an unknown pharmaceutical. Botulinum toxin type a was first approved as Dysport on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Trade Name Nuceiva
Common Name Botulinum toxin type a
Indication blepharospasm, dystonia, fissure in ano, genetic skin diseases, muscle rigidity, skin aging, strabismus
Drug Class Fluoroquinolone derivatives, nonantibacterial indications (e.g., antineoplastic antibiotics)
Botulinum toxin type a
Get full access now